SUSTIVA

This brand name is authorized in United States. It is also authorized in Austria, Canada, Estonia, France, Germany, Ireland, Lithuania, Poland, Spain, UK.

Active ingredients

The drug SUSTIVA contains one active pharmaceutical ingredient (API):

1	Efavirenz UNII JE6H2O27P8 - EFAVIRENZ
	Efavirenz is a NNRTI of HIV-1. Efavirenz is a non-competitive inhibitor of HIV-1 reverse transcriptase (RT) and does not significantly inhibit HIV-2 RT or cellular DNA polymerases (α, β, γ or δ).
	Read more about Efavirenz

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
STOCRIN Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AG03	Efavirenz	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AG Non-nucleoside reverse transcriptase inhibitors
Discover more medicines within J05AG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02239886, 02239888, 02246045
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	03155329, 03172486
EE	Ravimiamet	1202397, 1202409, 1202410, 1202421, 1202432, 1202454, 1414235
ES	Centro de información online de medicamentos de la AEMPS	99110001, 99110003
FR	Base de données publique des médicaments	60396426, 60798510, 63076285, 64702347
LT	Valstybinė vaistų kontrolės tarnyba	1030894, 1030895, 1030896, 1030897, 1030900, 1030901, 1030902, 1064318
PL	Rejestru Produktów Leczniczych	100316042, 100316059, 100316065, 100316088
US	FDA, National Drug Code	0056-0470, 0056-0474, 0056-0510